Read by QxMD icon Read

Unselected breast

J Jung, E Kang, J M Gwak, A N Seo, S Y Park, A S Lee, H Baek, S Chae, E K Kim, S W Kim
INTRODUCTION: BRCA mutation testing allows index patients and their families to be provided with appropriate cancer risk-reduction strategies. Because of the low prevalence of BRCA mutations in unselected breast cancer patients and the high cost of genetic testing, it is important to identify the subset of women who are likely to carry BRCA mutations. In the present study, we examined the association between BRCA1/2 germline mutations and the immunohistochemical features of breast cancer...
October 2016: Current Oncology
W Liu, J B Li, T Wang, L Bian, S H Zhang, H Q Zhang, J M Zhou, S T Song, Z F Jiang
Objective: To analyze the predict values of pathologic complete response (pCR) rates for patient outcome according to breast cancer (BC) molecular subtypes. Methods: Four hundred and sixteen patients with confirmed BC who received neoadjuvant chemotherapy (NCT) in The Affiliated Hospital of Military Medical Science Academy of the PLA were enrolled.The clinical and pathological characteristics of patients were collected. The primary endpoint was pCR rate and the secondary endpoint was disease free survival (DFS)...
September 27, 2016: Zhonghua Yi Xue za Zhi [Chinese medical journal]
P Whelehan, S H Heywang-Köbrunner, S J Vinnicombe, A Hacker, A Jänsch, A Hapca, R Gray, M Jenkin, K Lowry, R Oeppen, M Reilly, M Stahnke, A Evans
AIM: To compare the diagnostic accuracy of standard screening images plus single-view digital breast tomosynthesis (DBT), using Siemens DBT equipment, with standard screening images plus supplementary mammographic views in non-calcific, screen-detected mammographic abnormalities. MATERIALS AND METHODS: Participants were unselected women aged 50-69 years recalled within a population-based European breast screening programme for assessment of soft-tissue mammographic abnormalities...
October 10, 2016: Clinical Radiology
Pauline Bosco-Lévy, Jeremy Jové, Philip Robinson, Nicholas Moore, Annie Fourrier-Réglat, Julien Bezin
BACKGROUND: Non-persistence to oral hormonal therapy (HT) in breast cancer (BC) is an emerging health issue, and estimations vary according to the population selected and/or the statistical method applied. This study aimed to estimate non-persistence over 5 years to HT in an unselected sample of women with BC using a French national population-based database and accounting for competing risks. METHODS: A retrospective cohort of 600 women initiating a HT between 2006 and 2007 was constituted using a representative sample of the French national healthcare insurance system database...
October 11, 2016: British Journal of Cancer
Vincent Lebon, Jean-Louis Alberini, Jean-Yves Pierga, Véronique Diéras, Nina Jehanno, Myriam Wartski
: Breast cancer women younger than 40 years have a poorer outcome than older women. A higher rate of undetected metastasis at the time of diagnosis in young women has been proposed to account for this difference. Our main objective was to test this hypothesis by comparing the distant metastases rate (DMR) on initial FDG-PET/CT in a group of breast cancer patients younger than 40 years (<40y group) to a group of breast cancer patients older than 40 years (≥40y group). Assessment of associations between distant metastases and tumor characteristics was a second objective of the present study...
September 1, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Pedro Pinto, Ana Peixoto, Catarina Santos, Patrícia Rocha, Carla Pinto, Manuela Pinheiro, Luís Leça, Ana Teresa Martins, Verónica Ferreira, Carla Bartosch, Manuel R Teixeira
BRCA1 and BRCA2 mutations are responsible for hereditary breast and ovarian cancer, but they also confer an increased risk for the development of rarer cancers associated with this syndrome, namely, cancer of the pancreas, male breast, peritoneum, and fallopian tube. The objective of this work was to quantify the contribution of the founder mutations BRCA2 c.156_157insAlu and BRCA1 c.3331_3334del for cancer etiology in unselected hospital-based cohorts of Portuguese patients diagnosed with these rarer cancers, by using a strategy that included testing of archival tumor tissue...
2016: PloS One
Lee W Jones, Marilyn L Kwan, Erin Weltzien, Sarat Chandarlapaty, Barbara Sternfeld, Carol Sweeney, Philip S Bernard, Adrienne Castillo, Laurel A Habel, Candyce H Kroenke, Bryan M Langholz, Charles P Queensberry, Chau Dang, Britta Weigelt, Lawrence H Kushi, Bette J Caan
To investigate whether the impact of postdiagnosis exercise on breast cancer outcomes in women diagnosed with early-stage breast cancer differs on the basis of tumor clinicopathologic and molecular features. Using a prospective design, 6,211 patients with early-stage breast cancer from two large population-based cohort studies were studied. Age-adjusted and multivariable Cox regression models were performed to determine the relationship between exercise exposure (total MET-hours/week) and recurrence and breast cancer-related death for: (i) all patients ("unselected" cohort), and on the basis of (ii) classic clinicopathologic features, (iii) clinical subtypes, (iv) PAM50-based molecular intrinsic subtypes, and (v) individual PAM50 target genes...
September 15, 2016: Cancer Research
Qing-Bai She, Sofia K Gruvberger-Saal, Matthew Maurer, Yilun Chen, Mervi Jumppanen, Tao Su, Meaghan Dendy, Ying-Ka Ingar Lau, Lorenzo Memeo, Hugo M Horlings, Marc J van de Vijver, Jorma Isola, Hanina Hibshoosh, Neal Rosen, Ramon Parsons, Lao H Saal
BACKGROUND: The basal-like breast cancer (BLBC) subtype is characterized by positive staining for basal mammary epithelial cytokeratin markers, lack of hormone receptor and HER2 expression, and poor prognosis with currently no approved molecularly-targeted therapies. The oncogenic signaling pathways driving basal-like tumorigenesis are not fully elucidated. METHODS: One hundred sixteen unselected breast tumors were subjected to integrated analysis of phosphoinositide 3-kinase (PI3K) pathway related molecular aberrations by immunohistochemistry, mutation analysis, and gene expression profiling...
August 2, 2016: BMC Cancer
L Moscetti, P Vici, T Gamucci, C Natoli, E Cortesi, P Marchetti, D Santini, R Giuliani, I Sperduti, M Mauri, L Pizzuti, M L Mancini, M A Fabbri, V Magri, L Iezzi, V Sini, L D'Onofrio, L Mentuccia, A Vaccaro, S Ramponi, C L Roma, E M Ruggeri
PURPOSE: The everolimus and exemestane combination represents a treatment option for the endocrine sensitive metastatic breast cancer (MBC) patients. The toxicity profile reported in the Bolero 2 trial showed the feasibility in the selected patients. Few data are available for the unselected population. METHODS: In order to evaluate the safety in the unselected population of the clinical practice and to evaluate a possible association of toxicities with previous treatments, clinical data from 181 consecutive patients were retrospectively collected...
October 2016: Breast: Official Journal of the European Society of Mastology
Talia Donenberg, Humayun Ahmed, Robert Royer, Shiyu Zhang, Steven A Narod, Sophia George, Mohammad R Akbari, Jameel Ali, Judith Hurley
The mortality rate from breast cancer in the nation of Trinidad and Tobago is among the highest of any country in the Caribbean region. The contribution of inherited gene mutations to the burden of breast cancer in Trinidad and Tobago has not been studied. We examined the prevalence of mutations in three susceptibility genes (BRCA1, BRCA2, and PALB2) in breast cancer patients in Trinidad and Tobago. We studied 268 unselected breast cancer patients from Trinidad and Tobago and looked for mutations across the entire coding sequences of BRCA1, BRCA2, and PALB2...
August 2016: Breast Cancer Research and Treatment
Bárbara Alemar, Josef Herzog, Cristina Brinckmann Oliveira Netto, Osvaldo Artigalás, Ida Vanessa D Schwartz, Camila Matzenbacher Bittar, Patricia Ashton-Prolla, Jeffrey N Weitzel
Germline mutations in BRCA1 or BRCA2 (BRCA) are responsible for 5-15% of breast (BC) and ovarian cancers (OC), predisposing to the development of early onset and often multiple primary tumors. Since mutation carriers can benefit from risk-reducing interventions, the identification of individuals with hereditary breast and ovarian cancer (HBOC) syndrome has a significant clinical impact. We assessed whether a panel assay for recurrent Hispanic BRCA mutations (HISPANEL) has an adequate breadth of coverage to be suitable as a cost effective screening tool for HBOC in a cohort of patients from Southern Brazil...
June 20, 2016: Cancer Genetics
Katia Cannita, Stefania Paradisi, Valentina Cocciolone, Alberto Bafile, Lucia Rinaldi, Azzurra Irelli, Paola Lanfiuti Baldi, Luigi Zugaro, Rosa Manetta, Edoardo Alesse, Enrico Ricevuto, Corrado Ficorella
Angiogenesis plays an essential role in the growth and progression of breast cancer. This observational single center study evaluated the efficacy and safety of a new weekly schedule of bevacizumab/paclitaxel combination in the first-line treatment of unselected, HER2-negative, metastatic breast cancer (MBC) patients, in a real-life setting. Thirty-five patients (median age 56 years, range 40-81) with HER2-negative MBC were treated with paclitaxel (70 mg/m(2) ) dd 1,8,15 q21 (60 mg/m(2) if ≥65 years or secondary Cumulative Illness Rating Scale) plus bevacizumab (10 mg/kg) every 2 weeks...
September 2016: Cancer Medicine
Juan Zhang, Jie Sun, Jiuan Chen, Lu Yao, Tao Ouyang, Jinfeng Li, Tianfeng Wang, Zhaoqing Fan, Tie Fan, Benyao Lin, Yuntao Xie
We determined the prevalence and characteristics of BRCA1/2 germline mutations in a large cohort of Chinese women with breast cancer. A total of 5931 unselected Chinese women with breast cancer were enrolled in this study and underwent testing for BRCA1/2 mutations. Of these, 543 patients were familial breast cancer, 1033 were early-onset disease (≤40 years) without family history of breast cancer, and 4355 were sporadic breast cancer. In total, 232 patients (3.9 %) carried a BRCA1 or BRCA2 mutation (110 in BRCA1and 122 in BRCA2) in this cohort of 5931 patients...
August 2016: Breast Cancer Research and Treatment
S Chatterjee, M Arunsingh, S Agrawal, D Dabkara, A Mahata, I Arun, R K Shrimali, R Achari, I Mallick, R Ahmed
AIMS: Breast cancer is the most common cancer in women. Western data have confirmed hypofractionated radiation therapy to be safe and effective in the adjuvant radiation therapy of breast cancers. We report the disease-related outcomes in a non-Caucasian, unscreened population treated with hypofractionated radiation. MATERIALS AND METHODS: Unselected case notes of patients presenting to a tertiary cancer centre between June 2011 and December 2013 were reviewed from the electronic hospital case records...
October 2016: Clinical Oncology: a Journal of the Royal College of Radiologists
Joëlle Collignon, Laurence Lousberg, Hélène Schroeder, Guy Jerusalem
Triple-negative breast cancers (TNBCs) are defined by the absence of estrogen and progesterone receptors and the absence of HER2 overexpression. These cancers represent a heterogeneous breast cancer subtype with a poor prognosis. Few systemic treatment options exist besides the use of chemotherapy (CT). The heterogeneity of the disease has limited the successful development of targeted therapy in unselected patient populations. Currently, there are no approved targeted therapies for TNBC. However, intense research is ongoing to identify specific targets and develop additional and better systemic treatment options...
2016: Breast Cancer: Targets and Therapy
Xiaorong Zhong, Zhengwei Dong, Hua Dong, Jiayuan Li, Zuxiang Peng, Ling Deng, Xuehua Zhu, Yun Sun, Xuesong Lu, Fuxiao Shen, Xinying Su, Liying Zhang, Yi Gu, Hong Zheng
BACKGROUND: The prevalence of BRCA1/2 variants in Chinese breast cancer patients varies among studies. Germline or somatic BRCA1/2 mutations are associated with sensitivity to poly(ADP-ribose) polymerase-1 inhibitors and DNA-damaging agents. We aimed to investigate the distribution of both somatic and germline BRCA1/2 variants in unselected Chinese breast cancer patients, and explore their roles in tumor phenotype and disease prognosis. METHODS: 507 breast cancer patients, unselected for family history of breast cancer or age at diagnosis, were prospectively enrolled from West China Hospital between Feb...
2016: PloS One
Charlotte Warren-Gash, Mark Kroese, Hilary Burton, Paul Pharoah
BACKGROUND: The decision to test for high risk breast cancer gene mutations is traditionally based on risk scores derived from age, family and personal cancer history. Next generation sequencing technologies such as whole genome sequencing (WGS) make wider population testing more feasible. In the UK's 100,000 Genomes Project, mutations in 16 genes including BRCA1 and BRCA2 are to be actively sought regardless of clinical presentation. The implications of deploying this approach at scale for patients and clinical services are unclear...
2016: Hereditary Cancer in Clinical Practice
Uwe Güth, Dorothy Jane Huang, Johannes Bitzer, Rebecca Moffat
OBJECTIVES: Young women experience high levels of anxiety and distress during cancer diagnosis and therapy, and it can be devastating to become pregnant in this vulnerable state. Pregnancy during cancer treatment is strongly discouraged, as radiotherapy and chemotherapy administered during the first trimester of pregnancy result in increased congenital malformations. METHODS: In this study, we analysed an unselected, consecutive cohort of young breast cancer (BC) patients with regard to unintended pregnancy during the first year after BC diagnosis...
August 2016: European Journal of Contraception & Reproductive Health Care
Erica J Childs, Kari G Chaffee, Steven Gallinger, Sapna Syngal, Ann G Schwartz, Michele L Cote, Melissa L Bondy, Ralph H Hruban, Stephen J Chanock, Robert N Hoover, Charles S Fuchs, David N Rider, Laufey T Amundadottir, Rachael Stolzenberg-Solomon, Brian M Wolpin, Harvey A Risch, Michael G Goggins, Gloria M Petersen, Alison P Klein
Individuals from pancreatic cancer families are at increased risk, not only of pancreatic cancer, but also of melanoma, breast, ovarian, and colon cancers. While some of the increased risk may be due to mutations in high-penetrance genes (i.e., BRCA2, PALB2, ATM, p16/CDKN2A or DNA mismatch repair genes), common genetic variants may also be involved. In a high-risk population of cases with either a family history of pancreatic cancer or early-onset pancreatic cancer (diagnosis before the age of 50 years), we examined the role of genetic variants previously associated with risk of pancreatic, breast, ovarian, or prostate cancer...
July 2016: Cancer Epidemiology, Biomarkers & Prevention
C Winter, M P Nilsson, E Olsson, A M George, Y Chen, A Kvist, T Törngren, J Vallon-Christersson, C Hegardt, J Häkkinen, G Jönsson, D Grabau, M Malmberg, U Kristoffersson, M Rehn, S K Gruvberger-Saal, C Larsson, Å Borg, N Loman, L H Saal
BACKGROUND: A mutation found in the BRCA1 or BRCA2 gene of a breast tumor could be either germline or somatically acquired. The prevalence of somatic BRCA1/2 mutations and the ratio between somatic and germline BRCA1/2 mutations in unselected breast cancer patients are currently unclear. PATIENTS AND METHODS: Paired normal and tumor DNA was analyzed for BRCA1/2 mutations by massively parallel sequencing in an unselected cohort of 273 breast cancer patients from south Sweden...
August 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"